152 related articles for article (PubMed ID: 36827537)
1. Late onset vedolizumab-induced eosinophilic pneumonia in a patient with ulcerative colitis.
Faria LM; Oliveira MM; Faria AA; Vasconcellos AVO; Cançado GGL
Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):513-514. PubMed ID: 36827537
[No Abstract] [Full Text] [Related]
2. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.
Hinojosa Del Val J; Barreiro-de Acosta M
Gastroenterol Hepatol; 2019 Dec; 42(10):650-656. PubMed ID: 31635855
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
4. Vedolizumab: first global approval.
Poole RM
Drugs; 2014 Jul; 74(11):1293-303. PubMed ID: 24985716
[TBL] [Abstract][Full Text] [Related]
5. Vedolizumab for the treatment of ulcerative colitis.
Shahidi N; Bressler B; Panaccione R
Expert Opin Biol Ther; 2016; 16(1):129-35. PubMed ID: 26567768
[TBL] [Abstract][Full Text] [Related]
6. Mucosal Eosinophilia Is an Independent Predictor of Vedolizumab Efficacy in Inflammatory Bowel Diseases.
Kim EM; Randall C; Betancourt R; Keene S; Lilly A; Fowler M; Dellon ES; Herfarth HH
Inflamm Bowel Dis; 2020 Jul; 26(8):1232-1238. PubMed ID: 31633167
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence for vedolizumab: Understanding the landscape.
Lawrance IC; Pulusu SSR
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():28-29. PubMed ID: 30187556
[No Abstract] [Full Text] [Related]
8. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
9. Reply to comment on: "Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis".
Attauabi M; Seidelin JB; Burisch J
Dig Liver Dis; 2023 Feb; 55(2):300-301. PubMed ID: 36464612
[No Abstract] [Full Text] [Related]
10. Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.
Lam MC; Bressler B
Immunotherapy; 2014; 6(9):963-71. PubMed ID: 25341118
[TBL] [Abstract][Full Text] [Related]
11. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
[TBL] [Abstract][Full Text] [Related]
12. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
13. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
14. [Intestine selective therapy].
Maronde U
MMW Fortschr Med; 2015 Jul; 157(13):80. PubMed ID: 26206050
[No Abstract] [Full Text] [Related]
15. Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.
Lissner D; Glauben R; Allers K; Sonnenberg E; Loddenkemper C; Schneider T; Siegmund B
Am J Gastroenterol; 2018 Jan; 113(1):146-148. PubMed ID: 29311733
[No Abstract] [Full Text] [Related]
16. Herpes Zoster in a Patient With Ulcerative Colitis After Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?
Wu N; Li H; Zhang J; Huang W
Inflamm Bowel Dis; 2022 Feb; 28(2):e22-e23. PubMed ID: 34480561
[No Abstract] [Full Text] [Related]
17. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
18. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.
Rosario M; French JL; Dirks NL; Sankoh S; Parikh A; Yang H; Danese S; Colombel JF; Smyth M; Sandborn WJ; Feagan BG; Reinisch W; Sands BE; Sans M; Fox I
J Crohns Colitis; 2017 Aug; 11(8):921-929. PubMed ID: 28333288
[TBL] [Abstract][Full Text] [Related]
19. Respiratory Tract Infections in Patients With Inflammatory Bowel Disease: Safety Analyses From Vedolizumab Clinical Trials.
Feagan BG; Bhayat F; Khalid M; Blake A; Travis SPL
J Crohns Colitis; 2018 Jul; 12(8):905-919. PubMed ID: 29788248
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease.
Rosario M; Dirks NL; Gastonguay MR; Fasanmade AA; Wyant T; Parikh A; Sandborn WJ; Feagan BG; Reinisch W; Fox I
Aliment Pharmacol Ther; 2015 Jul; 42(2):188-202. PubMed ID: 25996351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]